<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">33403</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Editorial article</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Передовая статья</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Role of free radical oxidation in the development of cardiovascular events in chronic renal failure</article-title><trans-title-group xml:lang="ru"><trans-title>Роль свободнорадикального окисления в развитии сердечно-сосудистых осложнений при хронической почечной недостаточности</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Dzgoeva</surname><given-names>Fira Solomonovna</given-names></name><name xml:lang="ru"><surname>Дзгоева</surname><given-names>Фира Соломоновна</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра терапии факультета последипломного профессионального образованияд-р мед. наук, проф., зав. каф., каф. биохимии; ГОУ ВПО Северо-Осетинская государственная медицинская академия</p></bio><email>elena_takoeva@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Gatagonova</surname><given-names>Tamara Magometovna</given-names></name><name xml:lang="ru"><surname>Гатагонова</surname><given-names>Тамара Магометовна</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра терапии факультета последипломного профессионального образованияд-р мед. наук, проф., зав. каф; ГОУ ВПО Северо-Осетинская государственная медицинская академия</p></bio><email>nosma@dol.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Dzugkoeva</surname><given-names>Fira Solomonovna</given-names></name><name xml:lang="ru"><surname>Дзугкоева</surname><given-names>Фира Соломоновна</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра терапии факультета последипломного профессионального образованияд-р мед. наук, проф., зав. каф., каф. биохимии; ГОУ ВПО Северо-Осетинская государственная медицинская академия</p></bio><email>elena_takoeva@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kochisova</surname><given-names>Zalina Khasanovna</given-names></name><name xml:lang="ru"><surname>Кочисова</surname><given-names>Залина Хасановна</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра терапии факультета последипломного профессионального образованияаспирант; ГОУ ВПО Северо-Осетинская государственная медицинская академия</p></bio><email>kochisova_zalina@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kadzaeva</surname><given-names>Zarina Kazbekovna</given-names></name><name xml:lang="ru"><surname>Кадзаева</surname><given-names>Зарина Казбековна</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра терапии факультета последипломного профессионального образованияаспирант; ГОУ ВПО Северо-Осетинская государственная медицинская академия</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Khamitsaeva</surname><given-names>Ol'ga Vasil'evna</given-names></name><name xml:lang="ru"><surname>Хамицаева</surname><given-names>Ольга Васильевна</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра терапии факультета последипломного профессионального образованияаспирант; ГОУ ВПО Северо-Осетинская государственная медицинская академия</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Dzgoyeva</surname><given-names>F U</given-names></name><bio xml:lang="en"><p>Department of Therapy, Faculty of Postgraduate Medical Education, North Ossetian State Medical Academy</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Gatagonova</surname><given-names>T M</given-names></name><bio xml:lang="en"><p>Department of Therapy, Faculty of Postgraduate Medical Education, North Ossetian State Medical Academy</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Dzugkoyeva</surname><given-names>F S</given-names></name><bio xml:lang="en"><p>Department of Therapy, Faculty of Postgraduate Medical Education, North Ossetian State Medical Academy</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Kochisova</surname><given-names>Z Kh</given-names></name><bio xml:lang="en"><p>Department of Therapy, Faculty of Postgraduate Medical Education, North Ossetian State Medical Academy</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Kadzayeva</surname><given-names>Z K</given-names></name><bio xml:lang="en"><p>Department of Therapy, Faculty of Postgraduate Medical Education, North Ossetian State Medical Academy</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Khamitsayeva</surname><given-names>O V</given-names></name><bio xml:lang="en"><p>Department of Therapy, Faculty of Postgraduate Medical Education, North Ossetian State Medical Academy</p></bio><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">ГОУ ВПО Северо-Осетинская государственная медицинская академия</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Department of Therapy, Faculty of Postgraduate Medical Education, North Ossetian State Medical Academy</institution></aff><aff><institution xml:lang="ru"></institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2010-01-15" publication-format="electronic"><day>15</day><month>01</month><year>2010</year></pub-date><volume>82</volume><issue>1</issue><issue-title xml:lang="en">NO1 (2010)</issue-title><issue-title xml:lang="ru">№1 (2010)</issue-title><fpage>51</fpage><lpage>56</lpage><history><date date-type="received" iso-8601-date="2020-04-13"><day>13</day><month>04</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2010, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2010, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2010</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/33403">https://ter-arkhiv.ru/0040-3660/article/view/33403</self-uri><abstract xml:lang="en"><p>Aim. to refine a role of free radical oxidation (FRO), anemia, and endothelial dysfunction in the development of cardiovascular events in patients with chronic renal failure (CRF) at different stages of the disease.
Subjects and methods. Eighty-six patients, including 46 (53%) women and 40 (47%) men with Stages II-IV CRF, were examined. The patients' mean age was 43.6 ± 14 years. Echocardiography, measurements of the blood levels of hemoglobin, albumin, cholesterol, and uric acid, and determination of blood electrolytic composition were made. Blood creatinine concentrations in the group averaged 0.3 mmol/l. Glomerular filtration rate (GFR) calculated from the Cockroft-Goult formula averaged 33.96 ± 13 ml/min; the duration of CRF was 9.3 ± 1.6 years. Anemia was detected in 46 (53%) patients. Iron metabolism was estimated from serum ferritin levels. Special studies involved determination of FRO - malondialdehyde (MDA) and the activities of catalase and superoxide dismutase (SOD) in plasma and serum. The plasma concentrations of endohelin-1 (ET-1), thromboxane A2, and prostacyclin were measured by radioimmunoassay.
Results. The higher concentrations of MDA and the decreased activities of catalase and SOD, i.e. FRO, correlated with the progression of renal failure. There were also increases in the levels of ET-1 and thromboxane A2 and a reduction in the concentration of prostacyclin as blood creatinine levels elevated. Left ventricular hypertrophy was found in 43 (50%) of the 86 patients. Its severity depended on the decrease of creatine phosphokinase and the severity of anemia and arterial hypertension. There was a stable correlation between the changes in left ventricular myocardial mass, MDA levels, and catalase and SOD activities.
Conclusion. The higher level of MDA and the lower activities of catalase and SOD in patients with CRF, which correlate with diminished renal function, confirm that the disease is closely associated with FRO, that, by aggravating anemia and endothelial dysfunction, affects the magnitude of morphological and functional changes in the cardiovascular system in patients with CRF patients.</p></abstract><trans-abstract xml:lang="ru"><p>Цель исследования. Уточнить роль свободнорадикального окисления (СРО), анемии и дисфункции эндотелия в развитии сердечно-сосудистых осложнений у больных с хронической почечной недостаточностью (ХПН) на разных стадиях болезни.
Материалы и методы. Обследованы 86 пациентов - 46 (53%) женщин и 40 (47%) мужчин со II-IV стадией ХБП. Средний возраст больных составил 43,6 ± 14 лет. Проведены эхокардиография, определение уровня гемоглобина, альбумина, холестерина, мочевой кислоты крови, электролитного состава крови. Уровень креатинина крови в группе в среднем составил 0,3 ммоль/л. Скорость клубочковой фильтрации (СКФ) по формуле Кокрофта-Гоулта в среднем равнялась 33,96 ± 13 мл/мин, продолжительность ХПН - 3,6 ± 0,8 года. Артериальная гипертония (АГ) отмечена у 95% больных, длительность ее составила 9,3 ± 1,6 года. Анемия выявлена у 46 (53%) пациентов. Состояние обмена железа оценивали по уровню ферритина сыворотки. Специальные методы исследования включали определение факторов СРО - малонового диальдегида (МДА) и активности каталазы и супероксиддисмутазы (СОД) в плазме и сыворотке крови. Концентрацию в плазме эндотелина-1 (ЭТ-1), тромбоксана A2 и простациклина определяли методом радиоиммунного исследования.
Результаты. Повышение концентрации МДА, снижение активности каталазы и СОД, т. е. развитие СРО коррелировало с нарастанием почечной недостаточности. Повышение уровня ЭТ-1 и тромбоксана A2, снижение концентрации простациклина также отмечено по мере увеличения уровня креатинина крови. Гипертрофия левого желудочка выявлена у 43 (50%) из 86 больных. Ее выраженность зависела от степени снижения СКФ, тяжести анемии и АГ. Выявленная корреляция между изменениями показателей массы миокарда левого желудочка и уровнем МДА, активности каталазы и СОД носила устойчивый характер.
Заключение. Повышение уровня МДА и снижение активности каталазы и СОД у больных с ХПН, коррелирующие со степенью снижения функции почек, подтверждают, что заболевание тесно связано с СРО, который усугубляя анемию и дисфункцию эндотелия, влияет на степень морфологических и функциональных изменений сердечно-сосудистой системы больных с ХПН.</p></trans-abstract><kwd-group xml:lang="en"><kwd>chronic renal disease</kwd><kwd>free radical oxidation</kwd><kwd>anemia</kwd><kwd>endothelial dysfunction</kwd><kwd>left ventricular hypertrophy</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>хроническая болезнь почек</kwd><kwd>свободнорадикальное окисление</kwd><kwd>анемия</kwd><kwd>дисфункция эндотелия</kwd><kwd>гипертрофия левого желудочка</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Мухин Н. А., Моисеев В. С., Кабалава Ж. Д. и др. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Тер. арх. 2004; 6: 39-46.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Ma K. W., Greene E. L., Raij L. Cardiovascular risk factors in chronic renal failure and hemodialysis populations. Am. J. Kidney Dis. 1992; 19: 505-513.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Koch M., Gradaus F., Schoebel F. C. et al. Relevance of conventional cardiovascular risk factors for the prediction of coronary artery disease in diabetic patients on renal replacement therapy. Nephrol. Dial. Transplant. 1997; 12: 1187-1191.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Кутырина И. М., Руденко Т. И., Швецов М. Ю., Кушнир В. В. Роль ремоделирования крупных сосудов в развитии гипертрофии левого желудочка на додиализной стадии хронической почечной недостаточности. Тер. арх. 2008; 6: 37-41.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Dursun B., Dursun E., Suleymanlar G. et al. Carotid artery intima-media thickness correlates with oxidative stress in chronic haemodialysis patients with accelerated atherosclerosis. Nephrol. Dial. Transplant. 2008; 23: 1697-1703.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Glavind J., Hartmann S., Clemmesen J. et al. Studies on the role lipoperoxides in human pathology: II. The presence of peroxidize lipids in the atherosclerotic aorta. Acta Pathol. Microbiol. Scand. 1952; 30: 1-6.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Locatelli F., Canaud B., Eckardt K.-U. et al. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol. Dial. Transplant. 2003; 18: 1272-1280.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Vaziri N. D. Oxidative stress in uremia: nature, mechanisms, and potential consequences. Semin. Nephrol. 2004; 24: 469- 473.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Bhatia S., Shukla R., Venkata Madhu S. et al. Antioxidant status, lip peroxidation and nitric oxide end products in patients of type 2_ diabeti mellitus with nephropathy. Clin. Biochem. 2003; 36: 557-562.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Johnson F., Giulivi C. Superoxide dismutases and their impact upon human health. Mol. Aspects Med. 2005; 26: 340-352.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Sardenberg C., Suassuna P., Watanabe R. et al. Balance between cytokine production by peripheral blood mononuclear cells and reactive oxygen species production by monocytes in patients with chronic kidney disease. Ren. Fail. 2004; 26: 673-681.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Landmesser U., Merten R., Spiekermann S. et al. Vascular extracellular superoxide dismutase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation 2000; 101: 2264-2270.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Babior B. M. NADPH oxidase: an update. Blood 1999; 93: 1464-1476.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Stocker R., Keaney J. F., Jr. Role of oxidative modifications in atherosclerosis. Physiol. Rev. 2004; 84: 1381-1478.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Kojda G., Harrison D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc. Res. 1999; 43: 562-571.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Vanholder R., Massy Z., Argiles A. et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol. Dial. Transplant. 2005; 20: 1048-1056.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Redon J., Cea-Calvo L., Lozano J. V. et al. Kidney function and cardiovascular disease in the hypertensive population: the ERIC-HTA study. J. Hypertens. 2006; 24: 663-669.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Siems W., Sommerburg O., Grune T. Erythrocyte free radical and energy metabolism. Clin. Nephrol.; 53 (suppl. 1): 9-11.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Дзгоева Ф. У., Кутырина И. М. Тромбоксан А2 и простациклин у больных хроническим гломерулонефритом и ишемической болезнью сердца в условиях нефротоксического действия рентгеноконтрастных средств. Протективное действие антагонистов кальция. Тер. арх. 2000; 6: 42- 45.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Kalinina N., Agrotis A., Tararak E. et al. Cytochrome b558-dependent NAD(P)H oxidase-phox units in smooth muscle and macrophages of atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 2002; 22: 2037-2043.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Zalba G., Beloqui Q., San Jose G. et al. NADPH oxidase-dependent superoxide production is associated with carotid intima-media thickness in subjects free of clinical atherosclerotic disease. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 1452-1457.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Yilmaz M. I., Saglam M., Caglar K. et al. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am. J. Kidney Dis. 2006; 47: 42-50.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Zoccali C., Bode-Boger S., Mallamaci F. et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease. Lancet 2001; 358: 2113- 2117.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Dzgoeva F., Kutyrina I., Vanin A. et al. Decrease in kidney nitric oxide formation detected by electron paramagnetic resonance in acute renal failure. Nephron 1999; 81: 441.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Siems W., Quast S., Carluccio F. Oxidative stress in chronic renal failure as a cardiovascular risk factor. In: Hampl H., ed. Cardio renal anemia syndrome. Berlin: Dustri-Verlag; 2004. 16-26.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Violi F., Cangemi R. Antioxidants and cardiovascular disease. Curr. Opin. Invest. Drugs 2005; 6: 890-895.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Guzik T., Harrison D. Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discov. Today 2006; 11: 524-533.</mixed-citation></ref></ref-list></back></article>
